SCHEMBL5260906

SCHEMBL5260906

CC(C)(C)OC(=O)NC1CCCCC1(O)C(=O)Nc1ccnc2c(F)cc(F)cc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK8 P49336 1/20 0.41
GSK3A P49840 1/20 0.41
GSK3B P49841 1/20 0.41
CDK9 P50750 1/20 0.41
CDK5 Q00535 1/20 0.41
DYRK1B Q9Y463 1/20 0.41
F2R P25116 1/20 0.32
PARP1 P09874 2/20 0.32
TRPA1 O75762 2/20 0.32
SYK P43405 3/20 0.32
IDO1 P14902 1/20 0.32
CHRM1 P11229 2/20 0.31
NTRK1 P04629 4/20 0.31
MET P08581 2/20 0.31
KDR P35968 1/20 0.31
TEK Q02763 1/20 0.31
NTRK3 Q16288 1/20 0.31
NTRK2 Q16620 1/20 0.31
AXL P30530 1/20 0.31
AAK1 Q2M2I8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5635423 0.91 ALDH1A1 (0.35) CDK8GSK3AGSK3BCDK9CDK5
SCHEMBL3583797 0.80 JAK1 (0.35) CDK8GSK3AGSK3BCDK5KDR
SCHEMBL5263242 0.79 KCNH2 (0.42) GSK3AGSK3BKDR
SCHEMBL3580109 0.72 TYK2 (0.33)
SCHEMBL5264535 0.72 KCNH2 (0.37)
SCHEMBL3581635 0.72 ADAM17 (0.36) CDK5F2RSYKJAK2JAK1
SCHEMBL3581356 0.72 ADAM17 (0.34) F2RPARP1SYK
SCHEMBL3577828 0.71 MAPT (0.42)
SCHEMBL3574051 0.70 MTNR1A (0.39)
SCHEMBL5263146 0.68 ALDH1A1 (0.43) GSK3AGSK3BCDK9CDK5KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1399443-B1 NITROGEN-CONTAINING BICYCLIC HETEROCYCLES FOR USE AS ANTIBACTERIALS SMITHKLINE BEECHAM PLC (GB) 2007-12-12 EP disclosed
US-20070135422-A1 Nitrogen-containing bicycle heterocycles for use as antibacterials SMITHKLINE BEECHAM P.L.C. 2007-06-14 US disclosed
US-7141564-B2 Nitrogen-containing bicyclic heterocycles for use as antibacterials SMITHKLINE BEECHAM P.L.C. (GB) 2006-11-28 US disclosed
US-20040171620-A1 Nitrogen-containing bicyclic heterocycles for use as antibacterials SMITHKLINE BEECHAM P.L.C. (GB) 2004-09-02 US disclosed
EP-1399443-A1 NITROGEN-CONTAINING BICYCLIC HETEROCYCLES FOR USE AS ANTIBACTERIALS SMITHKLINE BEECHAM PLC (GB) 2004-03-24 EP disclosed
WO-2003087098-A1 NITROGEN-CONTAINING BICYCLIC HETEROCYCLES FOR USE AS ANTIBACTERIALS SMITHKLINE BEECHAM P.L.C. (GB) 2003-10-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040171620-A1 Nitrogen-containing bicyclic heterocycles for use as antibacterials NRDC, NUCB2, NDC1 CDK8 1996/4885GSK3A 4685/4885GSK3B 4650/4885
US-20070135422-A1 Nitrogen-containing bicycle heterocycles for use as antibacterials NRDC, NUCB2, NISCH CDK8 1353/4885GSK3A 4503/4885GSK3B 4468/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.